Ramona Sequeira has been named president of Takeda Pharmaceutical's U.S. subsidiary, Takeda Pharmaceuticals U.S.A., reporting directly to President and CEO Christophe Weber, effective June 1. Sequeira is currently a vice president of Eli Lilly.
Pfizer has a new vaccines R&D head in Kathrin Jansen, who will begin at the post on June 1. Previously CSO of Pfizer's vaccine research and early development, Jansen will report to global R&D president Mikael Dolsten and work out of Pfizer's Pearl River, New York research site.
Seunghee Kim, a veteran member of South Korea's Ministry of Food and Drug Safety, has been named to become its first female minister. Kim has a pharmacology degree from Seoul National University and a doctorate in biochemistry from Notre Dame.
The head of Cipla's India operations has resigned from his post just more than a year after joining from GlaxoSmithKline in January last year, the company said in an email to FiercePharmaAsia.
The fight for top bioinformatics talent is heating up. With 23andMe poaching Robert Gentleman from Genentech, the Roche-owned Big Biotech now finds itself competing with the likes of Google's Calico in its hunt for a replacement.
The Department of Homeland Security has named Marty Vanier of Kansas State University as the senior program manager for strategic partnership and development for the new National Bio and Agro-Defense Facility (NBAF) expected to by completed by 2018.
Takeda Pharmaceutical officially announced on March 5 that President and Chief Operating Officer Christophe Weber would become chief executive officer staring April 1, replacing Yasuchika Hasegawa.
SINGAPORE-- On Feb. 11, Otsuka Pharmaceutical appointed a new president, Tatsuo Higuchi, already president and CEO of the parent holding company, to replace Taro Iwamoto, who died two days earlier.
Under pressure from activist investor William Ackman of hedge fund Pershing Square Capital, animal health giant Zoetis said today it has named Ackman's colleague, William Doyle, to its board of directors. Doyle will serve on the board's corporate governance committee. Furthermore, Zoetis and Pershing Square have agreed to elect "an additional independent director mutually acceptable" to both companies, Zoetis said in a press release.
Last year the campaign for Chimerix to give an experimental cancer drug to a 7-year-old gave biopharma firms another reason to be wary of the power of social media. Having seen Chimerix be engulfed by the social media maelstrom, BIO is working to equip small biotechs with the skills they will need if they find themselves in a similar situation.